Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

 
• By Derrick Gingery
  
FDA Advisory Committee Feature image
The Dermatologic and Ophthalmic Drugs Advisory Committee voted 12-0 that teprotumumab's benefits outweighed risks.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers